Study: Epo is well tolerated in neonates with HIE

11/16/2012 | Medscape (free registration)

Early trial data showed erythropoietin, given in addition to hypothermia treatment, was well tolerated and may be neuroprotective for neonates with hypoxic-ischemic encephalopathy. Researchers at the University of California, San Francisco, said they plan to do a large randomized trial of Epo that will follow infants for two years to evaluate neurologic outcomes.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park